Eli Lilly (NYSE:LLY) Surges 5% Following Breakthrough BRAVE-AA-PEDS Study Results
Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...
Eli Lilly (NYSE:LLY) Advances Alopecia Study Results Amid 4% Share Price Rise
Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...
Where Will Eli Lilly Be in 5 Years?
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...
STAT2d
Lilly CEO got a big payday (and an Olympics treat)
Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...
STAT22h
Study reveals how often medical device makers report safety incidents late to FDA
Most medical devices in the United States come to market with limited clinical data, and device surveillance is viewed as a key way to keep patients safe. But the FDA’s system for collecting data and ...
Fierce Pharma8d
Lilly's first DTC Ebglyss campaign highlights eczema’s effects on a range of skin tones and age groups
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...
‘Miracle’ Alzheimer’s drug ‘triggers deadly brain bleeds in up to a third’, new study finds
AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...
Eli Lilly’s Ebglyss achieved ‘deep and sustained response’ in ADjoin study
New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...
Visa, Eli Lilly, Blackstone And A Real Estate Stock On CNBC's 'Final Trades'
On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm’s AI Transformation initiatives – ...
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results ...
Zacks Investment Research on MSN3d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
The Motley Fool11d
Where Will Eli Lilly Be in 5 Years?
Eli Lilly is set to keep ... Naturally, other new Lilly products could see the light of day by 2030, and others will progress to late-stage studies. That could be the case for the drugmaker's ...